Home › Cardinal Health to manufacture Bayer cancer drug in new Indiana facility
 

Keywords :   


Cardinal Health to manufacture Bayer cancer drug in new Indiana facility

2014-12-23 08:47:36| Chemicals - Topix.net

Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of the castration-resistant prostate cancer drug Xofigo . Under the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.

Tags: health drug cancer facility

Category:Chemicals

Latest from this category

All news
23.09Terrence Peters Joins Mule-Hide Products Co. as Territory Manager
21.09Weekly Recap: PPG, Axalta, AkzoNobel Top This Weeks Stories
20.09KANSAI HELIOS Further Expands as System Supplier in Italy
20.09New Acrylic Resin for Architectural Coatings Without Fluorosurfactants from EPS
20.09¦nie¿ka Publishes Results for 1H 2024
20.09Sheboygan Paint Company Appoints Fallon Phillip HR Director
20.09RadTech Europe (RTE) Sets Call for Papers
19.09Lubrizol Enhances Dispersant Production Capacity in North America
Chemicals »
23.09Price Ranch earns RAAA 2024 Commercial Producer of the Year
23.09Tropical Storm John Update Statement
23.09Summary for Tropical Storm John (EP5/EP102024)
23.09Is the Budget's bite going to be rather less painful than its bark?
23.09Flushability Standard Introduced in China
23.09Union boss questions Amazon public contracts
23.09Texas Landowners Advocate for Major Changes to Oilfield Waste Disposal Procedures
23.09Long Islands Waste Future Uncertain as Landfill Closure Looms
More »